AddedRisk Factors
•increasing our need to meet minimum net sales requirements when our future sales are uncertain;
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedRisk Factors
•limiting our flexibility in planning for, or reacting to, changes in our business and the industry in which we compete; and
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedRisk Factors
•placing us at a competitive disadvantage compared to our competitors that have less debt or better debt servicing options.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedRisk Factors
We intend to satisfy our current and future debt service obligations with our then-existing cash and cash equivalents. However, we may not have sufficient funds, and may be unable to arrange for additional financing, to pay the amounts due under the Loan Agreement or any other debt instruments. Failure to satisfy our current and future debt obligations, including covenants to take or avoid specific actions, under the Loan Agreement could result in an event of default and, as a result, the lender(s) could accelerate all of the amounts due, and the lender(s) could seek to enforce their security interests in any collateral securing such indebtedness. The lender(s) under the Loan Agreement have rights senior to our stockholders in receiving proceeds from a liquidation. In addition, the covenants under the Loan Agreement, and the pledge of our assets (including our intellectual property) as collateral could limit our ability to obtain additional debt financing. If we raise any additional debt financing, the terms of such additional debt could further restrict our operating and financial flexibility.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RemovedRisk Factors
Historically, direct inhibition of any RAS protein has been challenging due to a lack of tractable, or “druggable,” binding pockets. Given this approach is unproven, it may not be successful.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
Historically, direct inhibition of any RAS protein has been challenging due to a lack of tractable, or “druggable,” binding pockets. Our tri-complex technology has enabled us to design potent, cell-active inhibitors of multiple mutant RAS(ON) proteins. We are not aware of any programs in clinical development that have successfully targeted any RAS(ON) protein. We cannot be certain that our approach will lead to the development of approvable or marketable products, alone or in combination with other therapies.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
There are several programs in clinical development targeting KRAS G12C, including programs directed at KRAS(OFF) G12C being conducted by Amgen Inc., Betta Pharmaceuticals Co., Ltd., Bristol Myers Squibb Company, Chengdu Huajian Future Technology Co. Ltd., D3 BIO, Inc., Eli Lilly, GenEros Biopharma Ltd., Genhouse Bio Co. Ltd., Guangzhou BeBetter Medicine Technology Co., Ltd., HUYA Bioscience, Innovent Biologics, Inc. (licensed to Genfleet Therapeutics), InventisBio, Jacobio Pharmaceuticals Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Merck, Sharpe & Dohme LLC, Roche, Shanghai Junshi Biosciences Co., Ltd., Shanghai YingLi Pharmaceutical, Shouyao Holdings (Beijing) Co. Ltd. and Suzhou Zelgen Biopharmaceuticals. BridgeBio Pharma, Inc. and Frontier Medicines each have a dual KRAS(ON/OFF) G12C program in the clinic. There are also several clinical programs directed at KRAS G12D, including those being conducted by Astellas Pharma Inc., AstraZeneca, Eli Lilly, Genentech, Incyte Corporation, Jiangsu Hengrui Pharmaceuticals Company Ltd, Quanta Therapeutics, Tyligand Bioscience and Zelgen Biopharmaceuticals. In addition, there are a few clinical programs directed at KRAS G12V, including those being conducted by Affini-T Therapeutics and Yingkai Saiwei (Beijing) Biotechnology. Other clinical programs directed at mutant RAS, including pan-RAS inhibitors and Plk1 inhibitors, are being conducted, including those by Alaunos Therapeutics, Inc., BeiGene, Boehringer Ingelheim, Cardiff Oncology, Chugai Pharmaceutical Co., Ltd., Eli Lilly, Elicio Therapeutics, Gritstone bio, Inc., Moderna, Inc., Pfizer, Inc., Quanta Therapeutics, RasCal Therapeutics, Shanghai YingLi Pharmaceutical, Silenseed Ltd., Silexion Therapeutics and Targovax ASA. There are several programs in clinical development targeting SHP2, including those being conducted by Betta Pharmaceuticals Co., Ltd., Etern BioPharma (Shanghai) Co. Ltd., Genhouse Bio Co. Ltd., Hutchmed Ltd., HUYA Bioscience, InnoCare Pharma Ltd., Jacobio Pharmaceuticals Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Nanjing Sanhome Pharmaceutical, Navire Pharma, Inc., a BridgeBio company (licensed to Bristol Myers Squibb Company), Novartis AG, Relay Therapeutics, Inc. (licensed to Roche), Shanghai Gopherwood Biotech Co., Ltd., and Shanghai Ringene Biopharma Co., Ltd. The above list includes corporate competitors that we are currently aware of and that are currently conducting clinical trials or marketing in geographies where we currently anticipate conducting clinical trials for our product candidates. However, companies operating in other geographies, smaller companies and companies with earlier stage programs may also prove to be significant competitors. In addition, academic research departments and public and private research institutions may be conducting research on compounds that could prove to be competitive.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
Some of our programs focus on the discovery and development of “Beyond Rule of 5” small molecules. Such molecules can be associated with longer development timelines and greater costs compared to traditional small molecule drugs. Our “Beyond Rule of 5” product candidates may take longer to develop and/or manufacture relative to traditional small molecules, and we may not be able to formulate “Beyond Rule of 5” candidates for certain routes of administration.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
We enlist various technologies and capabilities that give us chemical access to challenging sites on target proteins that generally are not accessible using conventional small molecule drug discovery approaches. For each target, we consider the specific structural, physico-chemical, functional and dynamic properties of the target and deploy the approach or approaches that appear most likely to
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
yield viable development candidates. The “Rule of 5” is a set of criteria used in pharmaceutical drug development to determine whether chemical compounds have certain physico-chemical properties that make them likely to be orally active drugs in humans. In some instances, the compounds we discover and develop are traditional small molecules (i.e., less than 500 daltons) with properties that generally satisfy conventional pharmaceutical “Rule of 5” criteria, while in other cases, they are larger (i.e., more than 500 daltons) “Beyond Rule of 5” (BRo5) compounds that do not satisfy these criteria. For example, our mTORC1 program and our RAS(ON) inhibitors each include pursuit of BRo5 compounds.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
BRo5 compounds have been successfully pursued by many pharmaceutical companies. Examples of BRo5 compounds include natural products and semi-synthetic derivatives, peptidomimetics, macrocycles and degraders. However, larger molecular weight small molecules often cannot be formulated into orally absorbed drugs and also often face solubility, potency, bioavailability and stability challenges, among others. In addition, many of the commonly used predictive and other drug development tools are designed specifically for traditional “Rule of 5” small molecule drugs rather than BRo5 molecules, contributing to the difficulty and uncertainty of development of BRo5 compounds.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
Due to their size and complexity, drug development of our BRo5 compounds may be slower and/or more expensive than drug development of traditional “Rule of 5” compounds, resulting in program delays, increased costs or failure to obtain regulatory approval in a commercially reasonable timeframe, if at all. Our competitors developing traditional small molecules in areas where we are developing BRo5 compounds could obtain regulatory approval and reach the market before we do. Even if we succeed in generating an approved drug from a BRo5 compound, it may be less convenient to administer, have higher grade and/or more frequent side effects or be more costly to manufacture and formulate than competing products on the market. The discovery and development of BRo5 small molecules may pose risks to us such as:
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
•BRo5 small molecules may present difficult synthetic chemistry and manufacturing challenges, including with any scale-up of our product candidates in sufficient quality and quantity;
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
•BRo5 small molecules may be challenging to purify, including with any scale-up of our product candidates in sufficient quality and quantity;
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
•BRo5 small molecules may present oral absorption challenges due to low passive permeability, and may not achieve acceptable oral bioavailability for development and may result in poor pharmaceutical properties for formulation development;
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
•BRo5 small molecules may present cell permeability challenges, especially with regards to lipophilicity, hydrogen bond donor and rotatable bond count, and high topological polar surface area;
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RewordedRisk Factors
Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
We Other than the Royalty Purchase Agreement and the Term Loan Facility (which provide for additional funding subject to certain terms and conditions and trigger events), we do not have any committed external source of funds or other support for these activities, and we expect to may finance our cash needs through additional funding under the Royalty Purchase Agreement, the Term Loan Facility and/or a combination of public or private equity offerings, debt financings, other credit or loan facilities, acquisitions, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, even if we obtain while the FDA has granted orphan drug designation to daraxonrasib for the treatment of pancreatic cancer, the corresponding marketing exclusivity for such designation (and any future designations we may receive for a product candidate, that exclusivity candidate) may not effectively protect the product candidate from competition because different therapies can be approved for the same approved use or indication within the applicable disease or condition.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of any current or future product candidates or otherwise advance our business.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
We are evaluating certain of our product candidates in both exploratory and pivotal clinical trials, both as monotherapy and in combination regimens, and currently plan to conduct pivotal clinical trials for our RAS(ON) inhibitors, including the RASolute 302 study 302, RASolute 303, RASolute 304, RASolute 305, and the RASolve 301 study with daraxonrasib, both of which we recently initiated. 301.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
We recently initiated the are evaluating our product candidates in registrational trials, including RASolute 302 study 302, RASolute 303, RASolute 304, RASolute 305, and the RASolve 301 study with daraxonrasib, 301, and are currently planning additional registrational clinical trials for RMC-6236 daraxonrasib and our other RAS(ON) inhibitors.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
After March 2013, under the Leahy-Smith America Invents Act (the Leahy-Smith Act) enacted in September 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
The European Commission’s proposal for revision of several legislative instruments related to medicinal products was published in on April 2023, and would, among other things, potentially reduce the duration of regulatory data protection and revise the eligibility for expedited pathways. 26 2023.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
We have funded our operations to date primarily with proceeds from the sale of common stock and preferred stock, the acquisition of EQRx, and the Royalty Purchase Agreement, as well as upfront payments and research and development cost reimbursement received under our collaboration agreement with Genzyme Corporation, an affiliate of the Sanofi (the Sanofi Agreement). Agreement.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), Medicare, with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new manufacturer discounting program (which began in 2025).
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
Any failure or perceived failure by us to comply with federal, state or foreign laws or regulations, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Our product candidates will require substantial additional development time and resources before we will be able to apply for or receive regulatory approvals and, if approved, begin generating revenue from product sales.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
In addition, if If any of the research resulting in certain of our owned and/or in-licensed patent rights and technology were funded in part by the U.S. federal or state governments, the government would have certain rights, including march-in rights, to such patent rights and technology.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
We have designed a new class of RAS(ON) Inhibitors in order to overcome RAS-driven drug resistance and thereby extend the clinical benefit of RAS(ON) Inhibitors. We currently expect to initiate a first-in-human clinical trial from this class of RAS(ON) Inhibitors in the fourth quarter of 2026.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
Variants in RAS proteins are among the most common oncogenic drivers of cancer. Based on tumor mutation frequencies from Foundation Medicine data, scaled to estimated patient numbers using cancer incidence from the American Cancer Society Cancer Facts and Figures, there are an estimated more than 190,000 new RAS mutant cancer diagnoses each year in the U.S. These include approximately 60,000 patients with NSCLC, representing approximately 30% of NSCLC diagnoses, approximately 75,000 patients with colorectal cancer (CRC), representing approximately 50% of CRC diagnoses, and approximately 56,000 patients with PDAC, representing more than 90% of PDAC diagnoses.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
Pancreatic cancer is one of the most common and difficult-to-treat cancers and patients have historically had limited treatment options. Because of this unmet need and the prevalence of RAS as a driver of PDAC, we believe that pancreatic cancer represents a particularly compelling opportunity for RAS-targeted therapies.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
Based on encouraging early-stage clinical results, we are evaluating daraxonrasib and zoldonrasib in the following global, randomized Phase 3 registrational studies in PDAC:
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
•RASolute 302: comparing daraxonrasib against chemotherapy in patients with second line (2L) PDAC; a clinical readout for this study is currently expected in the first half of 2026;
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
•RASolute 303: comparing daraxonrasib with and without chemotherapy against chemotherapy in patients with first line (1L) metastatic PDAC;
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
•RASolute 304: evaluating daraxonrasib as an adjuvant therapy in patients with resectable PDAC; and
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
•RASolute 305: comparing zoldonrasib in combination with the investigator’s choice of either gemcitabine nab-paclitaxel or modified FOLFIRINOX against the investigator’s choice of the chemotherapies in patients with 1L metastatic PDAC in a placebo-controlled study.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
NSCLC is another major cancer type in which RAS mutations are common. While advances in immunotherapy and chemotherapy have improved outcomes for some individuals, many patients with RAS mutant NSCLC continue to experience disease progression, highlighting the need for new targeted approaches. Importantly, RAS mutations in NSCLC extend beyond a single subtype, leaving a significant portion of patients without broadly effective targeted treatment options.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
Based on encouraging early-stage clinical results we are evaluating daraxonrasib in RASolve 301, a global, randomized Phase 3 registrational trial comparing daraxonrasib versus docetaxel in patients with locally advanced or metastatic RAS mutant NSCLC who have been treated with immunotherapy and platinum-containing chemotherapy. We currently expect to substantially complete enrollment in RASolve 301 in 2026.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
We currently expect to provide an update on our plans for advancing daraxonrasib combination therapy in 1L NSCLC in 2026. We also currently expect to share an update on our registrational strategy for elironrasib in NSCLC in 2026.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
Colorectal cancers are genetically complex and heterogeneous, and patients with RAS mutant disease typically have limited targeted treatment options, particularly after progression on standard therapies. As a result, outcomes remain poor for many patients, underscoring the need for new therapeutic approaches that more effectively address the underlying drivers of the disease.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RemovedMD&A
Our research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which we refer to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways. Our RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
Our RAS(ON) Inhibitors are based on our proprietary tri-complex technology platform, which enables a highly differentiated approach to inhibiting the active, GTP-bound form of RAS, which we refer to as RAS(ON). We are developing a portfolio of compounds that we believe were the first RAS(ON) Inhibitors to use this mechanism of action. We believe that direct inhibitors of RAS(ON) suppress cell growth and survival and are less susceptible to adaptive resistance mechanisms recognized for RAS(OFF) inhibitors.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
We are evaluating our RAS(ON) Inhibitors alone and in combination with other drugs and investigational drug candidates, particularly in-pathway agents. We believe tailored RAS(ON) Inhibitors will be useful to serve the diverse landscape of RAS-addicted cancers optimally. We believe that in some cases, patients may experience maximal clinical benefit from the broad activity of our RAS(ON) multi-selective inhibitor, daraxonrasib (RMC-6236), if approved. In others, we believe treatment with a RAS(ON) mutant-selective inhibitor may be optimal. We further believe that in some cases, it could be beneficial to combine daraxonrasib with a RAS(ON) mutant-selective inhibitor, with daraxonrasib functioning as the backbone of these RAS(ON) Inhibitor doublets. In addition, we believe that in some cases, combination of our RAS(ON) Inhibitors with standard of care therapies, including immunotherapies, may be optimal.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
A global, randomized Phase 3 registrational trial of daraxonrasib in the second-line (2L) treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDAC), which we call the RASolute 302 study, is ongoing. In the RASolute 302 study, we are randomizing patients in a 1:1 ratio to receive either daraxonrasib at a dose of 300 mg daily or the investigator’s choice of chemotherapy. The RASolute 302 study has a nested trial design allowing for a hierarchical sequence of statistical analysis, with patients with tumors harboring RAS G12X mutations serving as the core population which will be tested first and all enrolled patients serving as the secondary population. We believe this nested design and hierarchical testing increases the probability of trial success based on the core population while creating an opportunity to gain approval for a broader population. Patients in the RASolute 302 study will be evaluated for the dual primary endpoints of progression-free survival (PFS) and overall survival (OS) in the core
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
population, with secondary endpoints including PFS and OS in the secondary population and objective response rate (ORR) and quality of life measures. We currently expect to substantially complete enrollment of the RASolute 302 study in 2025, to enable an expected clinical readout in 2026.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
Having finalized the study protocol, we are now activating sites for a global, randomized Phase 3 registrational trial comparing daraxonrasib versus docetaxel in patients with locally advanced or metastatic RAS-mutated non-small cell lung cancer (NSCLC) who have been treated with immunotherapy and platinum-containing chemotherapy, which we call the RASolve 301 study. In the RASolve 301 study, we are randomizing patients in a 1:1 ratio to receive either daraxonrasib or docetaxel. The RASolve 301 study has a nested trial design allowing for a hierarchical sequence of statistical analysis, with patients with tumors harboring RAS G12X (other than G12C) mutations serving as the core population which will be tested first, and all enrolled patients serving as the secondary population. We believe this nested design and hierarchical testing increases the probability of trial success based on the core population while creating an opportunity to gain approval for a broader population. Patients in the RASolve 301 study will be evaluated for the dual primary endpoints of PFS and OS in the core population, with secondary endpoints including PFS and OS in the secondary population and ORR and quality of life measures.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
On December 2, 2024 we reported updated clinical safety, tolerability, and activity data for daraxonrasib from our first-in-human monotherapy study of daraxonrasib, which we refer to as the RMC-6236-001 study, in patients with previously treated RAS-mutant PDAC as of a data cutoff date of July 23, 2024. We believe these data showed that daraxonrasib was generally well tolerated and demonstrated encouraging antitumor activity that supported our initiation of the RASolute 302 study.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
Also on December 2, 2024, we reported clinical safety and tolerability data as of a September 30, 2024 data cutoff date for daraxonrasib from the RMC-6236-001 study in patients with NSCLC with tumors harboring RAS mutations. We also reported clinical activity data as of a September 30, 2024 data cutoff date for daraxonrasib from the RMC-6236-001 study in patients with NSCLC with tumors harboring RAS G12X mutations who had received one or two prior lines of therapy which must have included prior immunotherapy and platinum chemotherapy administered either concurrently or sequentially, but not docetaxel, a study population matching the planned RASolve 301 enrollees. We believe these data showed that daraxonrasib was generally well tolerated and demonstrated encouraging antitumor activity that supported our initiation of the RASolve 301 study.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
Based on our observations from the RMC-6236-001 study and our preclinical observations, we believe there is a potential opportunity to evaluate daraxonrasib combinations in earlier lines of therapy in multiple tumor types, and we are currently evaluating several exploratory combination regimens that include daraxonrasib in order to assess the potential for development in these settings. These combinations include daraxonrasib with pembrolizumab, daraxonrasib with elironrasib, daraxonrasib with zoldonrasib and daraxonrasib with standard of care chemotherapy agents.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
On December 2, 2024, we disclosed initial clinical safety and tolerability data as of a data cutoff date of October 28, 2024 from our clinical study of the combination of daraxonrasib with pembrolizumab, which we believe showed the combination was generally well tolerated with limited hepatotoxicity.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
Also on December 2, 2024, we disclosed initial clinical safety, tolerability and activity data as of a data cutoff date of October 28, 2024 from our clinical study of the combination of daraxonrasib with elironrasib, which we believe showed the combination was generally well tolerated and provide initial proof-of-mechanism for a RAS(ON) inhibitor doublet in patients with colorectal cancer (CRC) who were previously treated with KRAS(OFF) G12C inhibitors. We believe these preliminary data observations support continued development of RAS(ON) inhibitor doublets in a broad range of tumor types and earlier lines of therapy, including 1L patients with NSCLC carrying RAS G12C tumors.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
In April 2024, at the American Association for Cancer Research (AACR) Annual Meeting 2024, we reported individual case studies from the RMC-6236-001 study that showed examples of objective responses to daraxonrasib in patients with tumor types beyond PDAC or NSCLC, specifically patients with melanoma and with CRC.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RewordedMD&A
The increase in research and development expenses during the year ended December 31, 2024 was primarily due to a $61.0 million increase in daraxonrasib expenses, primarily attributable to higher clinical trial and manufacturing expenses, including a $162.1 million increase related to daraxonrasib expenses, a $56.1 million increase related to zoldonrasib expenses and a $18.6 million increase related to elironrasib expenses; a $31.8 $75.6 million increase in salaries and other employee-related expenses due to increased headcount to support our research and development programs; a $23.5 million increase in zoldonrasib expenses, primarily attributable to higher clinical trial expenses; a $22.4 million increase in elironrasib expenses, primarily attributable to higher clinical trial expenses; a $16.8 million increase in stock-based compensation; a $14.9 $29.1 million increase in other research and development expenses as a result of higher rent, utilities and information technology expenses associated with increased headcount; a $27.4 million increase in stock-based compensation; and a $7.9 $19.8 million increase in preclinical research portfolio expenses; partially offset by a $9.3 million decrease in other RAS companion inhibitor program expenses.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
The change in operating assets and liabilities was primarily due to a $9.7 million increase in prepaid expenses and other current assets, a $5.9 million increase in other noncurrent assets, a $6.5 million decrease in accounts payable, offset by a $22.0 $112.3 million increase in accrued expenses and other current liabilities primarily related to clinical trial and clinical supply manufacturing expenses and increased personnel related expenses due to increased headcount and a $1.3 $9.5 million increase in accounts payable, offset by a $9.7 million increase in prepaid expenses and other current assets, a $12.9 million increase in other noncurrent assets, a $12.0 million increase in long-term deposits and a $1.0 million decrease in accounts receivable. operating lease liability.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Daraxonrasib (RMC-6236) $ 330,982 $ 168,911 $ 107,947 $ 60,964 162,071 Zoldonrasib (RMC-9805) 120,193 64,112 56,081 Elironrasib (RMC-6291) 73,671 55,034 32,593 22,441 Zoldonrasib (RMC-9805) 64,112 40,657 23,455 18,637 RMC-5127 12,824 — 12,824 RAS companion inhibitors 746 6,955 16,252 (9,297) (6,209) Preclinical programs 92,875 73,089 65,156 7,933 19,786 Total third-party research and development expenses 631,291 368,101 262,605 105,496 263,190 Salaries and other employee-related expenses 189,064 113,475 81,658 31,817 75,589 Stock-based compensation expense 78,356 50,973 34,126 16,847 27,383 Amortization of intangible assets 870 1,069 1,068 1 (199) Other research and development costs 87,751 58,607 43,687 14,920 29,144 Total research and development expense $ 987,332 $ 592,225 $ 423,144 $ 169,081 395,107
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in general and administrative expenses during the year ended December 31, 2024 was primarily due to a $6.7 $34.4 million increase in pre-commercial development commercial preparation expenses; a $4.5 $28.6 million increase in salaries and other employee-related expenses due to increased headcount; a $4.5 $11.8 million increase in stock-based compensation expense; a $10.2 million increase in legal and accounting fees; a $8.2 million increase in facilities and other allocated expenses as a result of higher rent, utilities and information technology expenses associated with increased headcount; and a $3.3 $2.9 million increase in legal and accounting fees; and a $1.2 million increase in insurance and other fees. professional expenses.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
During the year ended December 31, 2024, 2025, cash provided by financing activities of $959.4 $621.5 million was primarily comprised of $823.0 million in net proceeds from the issuance of common stock and pre-funded warrants from the December 2024 underwritten public offering, $118.7 $347.9 million in net proceeds from the issuance of common stock under the 2024 ATM and ATM, $244.2 million in net proceeds from the 2021 ATM, $12.3 sale of future royalties, $21.1 million in proceeds from the issuance of common stock upon the exercise of stock options and $5.0 $8.0 million in proceeds from the issuance of common stock under the employee stock purchase plan.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
During the year ended December 31, 2023, 2025, cash used in provided by investing activities of $342.6 $118.1 million was primarily comprised of cash provided by maturities of marketable securities of $1.9 billion and sale of marketable securities of $6.4 million, offset by purchases of marketable securities of $1.1 $1.8 billion and purchases of property and equipment of $7.7 million, offset by cash provided by maturities of marketable securities of $724.0 $16.0 million.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
We Other than the Royalty Purchase Agreement and the Term Loan Facility (which provide for additional funding subject to certain terms and conditions and trigger events), we do not have any committed external source of funds or other support for these activities, and we expect to may finance our cash needs through additional funding under the Royalty Purchase Agreement, the Term Loan Facility and/or a combination of public or private equity offerings, debt financings, other credit or loan facilities, acquisitions, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Our To date, our operations have been financed primarily by our public offerings of common stock, the EQRx Acquisition and $188.7 million received under the Sanofi Agreement from June 2018 through June 2023 for upfront payments and for research and development cost reimbursement. sale of future royalties.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
We also currently expect to initiate RASolve 308, a global, randomized placebo-controlled Phase 3 daraxonrasib monotherapy study registrational trial evaluating zoldonrasib in combination with standard of care in patients with first-line (1L) 1L metastatic PDAC RAS G12D NSCLC in the second first half of 2025. 2026.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
In August 2024, February 2026, we terminated the 2021 2024 ATM and entered into a new sales agreement with TD Cowen to sell shares of our common stock, from time to time, with aggregate gross proceeds of up to $500 million, $1 billion, through an at-the-market equity offering program (the 2024 ATM). 2026 ATM) under which TD Cowen agreed to act as our sales agent.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
We currently In addition, we expect to initiate RASolute 309, a global, randomized Phase 3 registrational trial evaluating the combination of daraxonrasib monotherapy study with zoldonrasib in patients with first-line (1L) metastatic 1L PDAC in the second half of 2025. 2026.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Change in fair value of warrant liability and contingent earn-out shares, consists of change in fair value of warrants and earn-out shares 4,323 115 4,208 assumed as part of the EQRx, Inc. acquisition.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
Quiet changesMD&A
Each pre-funded warrant will be is exercisable from the date of issuance until fully exercised, subject to an ownership limitation.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
Quiet changesMD&A
We will require substantial additional financing funds for our development efforts for our current and future programs and to prepare for their potential commercialization.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new